FDA Clears Once-Daily Raltegravir (Isentress HD) for HIV

Megan Brooks

May 31, 2017

The US Food and Drug Administration (FDA) has approved a new 1200-mg once-daily version of the integrase inhibitor raltegravir (Isentress HD, Merck), the company has announced.

Isentress HD is given in two 600-mg film-coated tablets with or without food, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and children weighing at least 40 kg who are treatment-naive or whose virus has been suppressed on an initial regimen of raltegravir 400 mg twice daily, the company said in a news release.

"Isentress has been used as a component of treatment regimens for patients diagnosed with HIV-1 for almost a decade," Michael S. Saag, MD, director of the Center for AIDS Research at the University of Alabama at Birmingham School of Medicine, said in the release.

"The addition of a convenient once-daily version with a comparable efficacy and safety profile at 48 weeks to the existing twice-daily version of Isentress provides physicians with a new therapeutic option for some patients with HIV-1 infection," he added.

The FDA approved the 1200-mg once-daily raltegravir dose on the basis of data from the phase 3 ONCEMRK trial. At week 48, 89% of treatment-naive HIV-1-infected patients receiving once-daily raltegravir achieved viral suppression of HIV-1 RNA <40 copies/mL compared to 88% of patients receiving raltegravir 400 mg twice a day, each in combination therapy with emtricitabine plus tenofovir disoproxil fumarate (treatment difference, 0.5; 95% confidence interval, -4.2 to 5.2).

The finding was consistent across demographic groups at initiation of therapy and a variety of patient populations, including those with high viral load (HIV-1 RNA >100,000 copies/mL), the company said.

The rate of discontinuance of therapy due to adverse events was low (1% in patients receiving raltegravir 1200 mg once daily and 2% in those receiving 400 mg twice daily), the company said.

No drug-related clinical adverse reactions of moderate to severe intensity occurred in 2% or more of patients in either treatment group. Clinical adverse reactions of all intensities (mild, moderate, and severe) occurring in 2% or more of patients taking once-daily or twice-daily raltegravir included abdominal pain, diarrhea, vomiting, and decreased appetite. Treatment-emergent viral mutations leading to any drug resistance were detected in fewer than 1% of patients taking raltegravir once daily.

Merck said the price of once-daily Isentress HD will be the same as twice-daily Isentress. They expect Isentress HD to be available in US pharmacies in about 4 weeks.

For more news, join us on Facebook and Twitter


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.